Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824

PA-824 is a novel nitroimidazo-oxazine under evaluation as an antituberculosis agent. A dose-ranging randomized study was conducted to evaluate the safety, tolerability, pharmacokinetics, and early bactericidal activity of PA-824 in drug-sensitive, sputum smear-positive adult pulmonary-tuberculosis...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Diacon, Andreas H., Dawson, Rodney, du Bois, Jeannine, Narunsky, Kim, Venter, Amour, Donald, Peter R., van Niekerk, Christo, Erondu, Ngozi, Ginsberg, Ann M., Becker, Piet, Spigelman, Melvin K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2012
Soggetti:
Clinical Therapeutics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3370777/
https://ncbi.nlm.nih.gov/pubmed/22430968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.06125-11
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi